How Policy Choices Cost Europe Its Biopharma Leadership: Lessons for the Global Innovation Race

A cautionary tale of price controls, regulatory constraints, and the shifting geography of life sciences R&D.

Executive Summary

For much of the 20th century, Europe stood as the world’s epicenter of biopharmaceutical innovation. Today, that mantle has moved across the Atlantic, a shift driven not by chance but by deliberate policy decisions. A new report from the Information Technology and Innovation Foundation (ITIF) chronicles how Europe’s adoption of stringent price controls and restrictive regulations weakened incentives for R&D, delayed drug launches, and triggered a loss of high-value life sciences jobs. The report cautions that the United States, now facing its own policy debates, risks repeating Europe’s errors. With China mounting a determined push to dominate the next generation of life sciences, the stakes are global.

Introduction

Biopharmaceutical innovation is central to public health, economic competitiveness, and even geopolitical influence. Over the past four decades, the industry’s center of gravity has shifted decisively. Europe, which once produced the majority of new medicines, now contributes only a fraction of the global pipeline. The United States has become the dominant hub for drug discovery, funded by a supportive ecosystem and a large, relatively open market. This transformation provides essential lessons for policymakers everywhere, especially those considering measures that could either enhance or undermine national innovation capacity.

Background & Context

Europe’s decline is striking in historical perspective. Between 1960 and 1965, European firms developed 65 percent of all new medicines. Into the 1970s, they introduced more than twice as many new drugs as their U.S. counterparts. As late as 1990, Europe accounted for half of global biopharmaceutical R&D investment, with industry spending roughly 50 percent higher than that in the United States. Yet this began to change rapidly in the 1990s. By 2004, Europe’s share of global pharmaceutical innovation had fallen to 18 percent, while the U.S. share had soared to 62 percent. European R&D investment growth lagged, and global companies increasingly launched new therapies first in the United States, a pattern reflecting both capital flight and market attractiveness.

Main Analysis

The ITIF report attributes Europe’s fall to a series of policy interventions, most notably price controls. Beginning in the 1980s, many European governments implemented reference pricing, profit caps, and other mechanisms to limit drug spending. These measures aimed to improve affordability, but they also reduced the financial returns on high-risk R&D. With prices suppressed and market access uncertain, companies found it harder to justify large investments in the region. In addition, restrictive regulations on biotechnology research and entrepreneurship further dampened innovation.

The consequences were measurable. Across Europe, fewer drugs were brought to market, launches were delayed, and high-paying life sciences jobs disappeared. For patients in 22 of 27 EU countries, the median delay from regulatory approval to payer coverage for novel treatments exceeded one year, compared with faster access in the United States. In 25 of 27 EU countries, time to availability was longer than in the United States. In effect, Europe’s cost-containment policies reduced the very innovation that underpins new treatment options and economic vitality.

Global Impact

The reshaping of the biopharmaceutical landscape has profound global implications. The location of R&D and manufacturing determines where the next generation of therapies will emerge, which economies enjoy high-value employment, and how supply chains are structured. The United States’ ascendancy was a direct consequence of Europe’s retreat, but that leadership is now imperiled by proposed U.S. policies. Tariffs on medicines and active pharmaceutical ingredients, weakened intellectual property protections, and cuts to basic research funding are all threats. Should the United States retreat, it would not only harm American patients but could also stall the global pipeline of innovative medicines.

Meanwhile, China is moving deliberately to become the next biopharma superpower. With robust state support, a growing science base, and expanding manufacturing capacity, China could fill any void left by the West. The global balance of life sciences innovation is therefore a contested, policy-driven landscape—not a fixed hierarchy.

Strategic Insights

The report offers both warnings and constructive alternatives. To sustain innovation, governments must protect intellectual property, ensure predictable market access, and invest in foundational research. Policies that encourage advanced manufacturing, public-private partnerships, and more equitable international cost sharing can enhance innovation while preserving patient access. For Europe, recent initiatives such as the “Choose Europe” campaign to attract global talent and Germany’s effort to move away from international reference pricing signal a recognition of past mistakes. These will take time to bear fruit, but they represent necessary corrections.

For the United States, the strategic insight is clear: avoid replicating Europe’s mistakes. A commitment to innovation-friendly policies will not only yield better health outcomes but also support economic growth and national security. As other countries adapt, the U.S. cannot afford complacency.

Future Outlook

Over the next 3–10 years, the global biopharmaceutical landscape will be shaped by technological advances—from artificial intelligence to genomics—and by geopolitical competition. If the United States adopts restrictive measures, it risks ceding ground to China, which is actively building a parallel innovation ecosystem. Europe’s recovery, while plausible, faces structural barriers and may proceed slowly. The most effective approach for all countries is to align incentives for R&D with the goal of broad patient access, while distributing the costs of innovation equitably across the global economy.

Conclusion

Europe’s loss of biopharma leadership is a cautionary tale about the unintended consequences of well-intentioned policies. The rise of the United States was not preordained; it was earned through deliberate policy choices. Similarly, the future of global life sciences innovation will be written by today’s decisions. Policymakers worldwide should internalize the lessons from Europe’s experience and its tentative recovery efforts, recognizing that the ultimate winners are the patients and economies that depend on a vibrant, innovative biopharmaceutical ecosystem.

---

Key Takeaways

• Europe’s biopharma leadership eroded due to stringent price controls and restrictive regulations.
• Price controls led to fewer new drugs, delayed launches, reduced R&D investment, and job losses.
• U.S. policy proposals—tariffs, IP erosion, funding cuts—threaten the ecosystem underpinning its leadership.
• China is actively vying for global biopharma dominance.
• Constructive alternatives include advanced manufacturing incentives, public-private partnerships, and equitable global cost sharing.

Sources

• ITIF. “Lessons From Europe’s Loss of Biopharma Leadership, and Its Attempts to Recover.” March 18, 2026. https://itif.org/publications/2026/03/18/lessons-from-europes-loss-of-biopharma-leadership-and-attempts-to-recover